Innovative technologies to improve drug-candidate selection and clinical-trial design.
SAN JOSE, Calif., July 30, 2024 /PRNewswire/ — Verseon and NeuTherX are pleased to announce their partnership to accelerate drug development through the use of NeuTherX’s scalable organoid development technology.
Verseon continues to streamline every aspect of creating medicines that will improve how the world treats all major human diseases. Characterizing the behavior of drugs in humans has historically required extensive clinical trials, which entail considerable time and cost.
Any lab-derived early insight into how drugs will behave in human patients can make drug trials vastly more efficient. To that end, Verseon has been developing organoid-based technology to characterize drugs. Organoids are artificially grown masses of cells that resemble the function of specific human organs. Testing drugs on organoids can deliver valuable information on the potential effects of drugs in real patients before any human is dosed.
While Verseon continues to internally develop its groundbreaking suite …